First drug for acute graft-versus-host disease prevention approved by FDA
BMS’s Orencia (abatacept) has been approved by the US FDA for prophylaxis of acute graft-versus-host disease (aGvHD) in patients aged two years plus.
List view / Grid view
BMS’s Orencia (abatacept) has been approved by the US FDA for prophylaxis of acute graft-versus-host disease (aGvHD) in patients aged two years plus.
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...